类风湿关节炎(RA)是一种自身免疫性疾病，将导致炎症和关节破坏。尽管抗风湿药物具有一定的广谱性，但是由于类风湿关节炎是一种存在多种发病原因和机制的异质性疾病，超过30%的患者的类风湿关节炎并没有得到很好的控制。

        2015年4月在《Trends in pharmacological sciences》(药理学趋势)杂志发表了一篇文章，提出两种新的风湿病治疗途径，涉及两种新的治疗靶点：Janus激酶(JAK)通路和T helper-17(Th17)通路[包括白细胞介素IL17，IL-21，IL-22，和粒细胞-巨噬细胞集落刺激因子(GM-CSF)]。文章也对目前能够通过这些途径治疗的潜在生物制剂和小分子抑制剂进行了综述。文章指出联合用药，并筛选相关生物标志物，将有助于实现RA患者的有效个性化治疗。

        摘要原文：

        Trends Pharmacol Sci. 2015 Apr;36(4):189-195. doi: 10.1016/j.tips.2015.02.001. Epub 2015 Feb 27.

        Novel therapeutic targets in rheumatoid arthritis.

        Koenders MI1, van den Berg WB2.

        Author information

        Abstract

        Rheumatoid arthritis (RA) is an autoimmune disease that leads to inflammation and destruction of synovial joints. Despite the broad spectrum of antirheumatic drugs, this heterogeneous disease is still not well controlled in up to 30% of patients. Here, we discuss two pathways that are regarded as interesting novel therapeutic targets in the field of rheumatology: the Janus kinase (JAK) pathway and the T helper-17 (Th17) pathway [including interleukin (IL)-17, IL-21, IL-22, and granulocyte-macrophage colony-stimulating factor (GM-CSF)]. We also review the therapy potential of biologicals and small-molecule inhibitors blocking these pathways. Advances in combination therapy in addition to progress in biomarker screening will help us to further achieve effective and personalized healthcare for patients with RA.